Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
about
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations.Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regressionSquamous cell transformation and EGFR T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report.Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer.[Influence of Different Therapies on EGFR Mutants by Circulating Cell-free DNA of Lung Adenocarcinoma and Prognosis].MicroRNAs associated with therapy of non-small cell lung cancer.
P2860
Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Clinical outcomes of EGFR-TKI ...... mutations on exons 19 and 21.
@ast
Clinical outcomes of EGFR-TKI ...... mutations on exons 19 and 21.
@en
type
label
Clinical outcomes of EGFR-TKI ...... mutations on exons 19 and 21.
@ast
Clinical outcomes of EGFR-TKI ...... mutations on exons 19 and 21.
@en
prefLabel
Clinical outcomes of EGFR-TKI ...... mutations on exons 19 and 21.
@ast
Clinical outcomes of EGFR-TKI ...... mutations on exons 19 and 21.
@en
P2093
P2860
P1476
Clinical outcomes of EGFR-TKI ...... mutations on exons 19 and 21.
@en
P2093
Jian-Chun Duan
Jiang-Yong Yu
Shu-Hang Wang
Tong-Tong An
P2860
P2888
P356
10.1186/S40880-016-0086-2
P577
2016-03-21T00:00:00Z